Johnson & Johnson Stock Up 62% on 7.9% Q4 Sales Growth and $100.5B Guidance
Johnson & Johnson shares have surged 62% over the past year as a leaner post-spinoff structure and high margins boost cash flow and debt metrics. Q4 Innovative Medicine sales grew 7.9%, FY2026 revenue is guided to $100.5 billion, and the $3.05 billion Halda acquisition plus a $5 billion-potential pipeline underpin growth.
1. Stock Performance and Momentum
Johnson & Johnson shares have gained 62% over the last 12 months, shifting perception from a defensive conglomerate to a high-quality compounder. This momentum reflects strong free cash flow, robust margins and a low-debt capital structure that attract growth-focused investors.
2. Innovative Medicine Portfolio Growth
Q4 2025 Innovative Medicine sales grew 7.9%, driven by volume-led growth in Darzalex, Carvykti and Tremfya. This segment’s strength offset double-digit Stelara biosimilar erosion, underscoring resilience in the core pharmaceutical division.
3. Strategic Acquisitions and Pipeline Expansion
The $3.05 billion acquisition of Halda Therapeutics adds a RIPTAC prostate cancer platform, while MedTech integration of Shockwave Medical and VARIPULSE Plus launch bolster cardiovascular growth. The pipeline now includes over 10 assets with collective peak sales potential above $5 billion, including the OTTAVA robotic surgery system.
4. Outlook and Risks
Management guides FY2026 revenues to $100.5 billion, projecting 6.7% growth despite pricing concessions and competition. However, biosimilar threats to Stelara and ongoing legal overhangs represent key risks to margin stability and share performance.